Dual cholinesterase inhibitor (ChEI); inhibits both butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). Brain penetrant.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 400.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.5 mL||12.49 mL||24.97 mL|
|5 mM||0.5 mL||2.5 mL||4.99 mL|
|10 mM||0.25 mL||1.25 mL||2.5 mL|
|50 mM||0.05 mL||0.25 mL||0.5 mL|
References are publications that support the biological activity of the product.
Groner et al (2007) The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol.Pharmacol. 71 1610 PMID: 17347320
Luo et al (2006) Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J.Med.Chem. 49 2174 PMID: 16570913
Mehta et al (2012) New acetylcholinesterase inhibitors for Alzheimer's disease. Int.J.Alzheimers Dis PMID: 22216416
Bailey et al (2011) Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6 e21954 PMID: 21799757
If you know of a relevant reference for Rivastigmine tartrate, please let us know.
View Related Products by Product Action
Keywords: Rivastigmine tartrate, Rivastigmine tartrate supplier, acetylcholinesterase, AChE, butyrylcholinesterase, BChE, inhibitors, inhibits, ChEI, brain, penetrant, ENA713, Rivastigmine, tartrate, ENA, 713, Cholinesterases, 4440, Tocris Bioscience
1 Citation for Rivastigmine tartrate
Citations are publications that use Tocris products. Selected citations for Rivastigmine tartrate include:
Budzynska et al (2015) Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Curr Alzheimer Res 232 931 PMID: 25189792
Do you know of a great paper that uses Rivastigmine tartrate from Tocris? Please let us know.
Reviews for Rivastigmine tartrate
There are currently no reviews for this product. Be the first to review Rivastigmine tartrate and earn rewards!
Have you used Rivastigmine tartrate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.